Evidence map›Paper›PMID 31521172›Full record

ReviewLipids in health and disease2019

Sialic acid metabolism as a potential therapeutic target of atherosclerosis.

Chao Zhang, Jingyuan Chen, Yuhao Liu, Danyan Xu

Open access · goldAbstract readReview
In one paragraph

Review in Lipids in health and disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 83 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Atherosclerosis: A Comprehensive Review of Molecular Factors and Mechanisms.International journal of molecular sciences · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Recent advances onSynthetic and systems biotechnology · 2023
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Sialic acid as the potential link between lipid metabolism and inflammation in the pathogenesis of atherosclerosis.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2023
    Review
  17. EarlyFrontiers in oncology · 2023
    Article
  18. Article
  19. Article
  20. Sialidase Inhibitors with Different Mechanisms.Journal of medicinal chemistry · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Chao ZhangDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, 139 Middle Renmin Road, Changsha, 410011, Hunan, China.
Jingyuan ChenDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, 139 Middle Renmin Road, Changsha, 410011, Hunan, China.
Yuhao LiuDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, 139 Middle Renmin Road, Changsha, 410011, Hunan, China.
Danyan XuDepartment of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, 139 Middle Renmin Road, Changsha, 410011, Hunan, China. xudanyan02@csu.edu.cn.
Central South University · CNSecond Xiangya Hospital of Central South University · CN

Funding

the National Nature Scientific Funding of China No.81672264, No.81372117
6 · The paper itself

Abstract

Sialic acid (Sia), the acylated derivative of the nine-carbon sugar neuraminic acid, is a terminal component of the oligosaccharide chains of many glycoproteins and glycolipids. In light of its important biological and pathological functions, the relationship between Sia and coronary artery disease (CAD) has been drawing great attentions recently. Large-scale epidemiological surveys have uncovered a positive correlation between plasma total Sia and CAD risk. Further research demonstrated that N-Acetyl-Neuraminic Acid, acting as a signaling molecule, triggered myocardial injury via activation of Rho/ROCK-JNK/ERK signaling pathway both in vitro and in vivo. Moreover, there were some evidences showing that the aberrant sialylation of low-density lipoprotein, low-density lipoprotein receptor and blood cells was involved in the pathological process of atherosclerosis. Significantly, the Sia regulates immune response by binding to sialic acid-binding immunoglobulin-like lectin (Siglecs). The Sia-Siglecs axis is involved in the immune inflammation of atherosclerosis. The generation of Sia and sialylation of glycoconjugate both depend on many enzymes, such as sialidase, sialyltransferase and trans-sialidase. Abnormal activation or level of these enzymes associated with atherosclerosis, and inhibitors of them might be new CAD treatments. In this review, we focus on summarizing current understanding of Sia metabolism and of its relevance to atherosclerosis.

Indexed as

AnimalsAtherosclerosisEnzyme InhibitorsExtracellular Signal-Regulated MAP KinasesGene Expression RegulationGlycoproteinsHumansLDL-Receptor Related ProteinsLipoproteins, LDLMAP Kinase Kinase 4Molecular Targeted TherapyN-Acetylneuraminic AcidNeuraminidaserho-Associated KinasesSialic Acid Binding Immunoglobulin-like LectinsSialyltransferasesEnzyme InhibitorsExtracellular Signal-Regulated MAP KinasesGlycoproteinsLDL-Receptor Related ProteinsLipoproteins, LDLMAP Kinase Kinase 4N-Acetylneuraminic AcidNeuraminidaserho-Associated KinasesSialic Acid Binding Immunoglobulin-like LectinsSialyltransferasestrans-sialidaseAtherosclerosisSialic acidSialidaseSialyltransferaseTrans-sialidase

Identifiers

PMID31521172
PMCPMC6745061
OpenAlexW2972593649

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.